Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
about
A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicityProgressive degeneration of human neural stem cells caused by pathogenic LRRK2The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutationEmerging preclinical pharmacological targets for Parkinson's diseaseHeterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsInhibition of LRRK2 kinase activity stimulates macroautophagyParkinson's disease-implicated kinases in the brain; insights into disease pathogenesis.LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organsThe function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic NeurotransmissionContribution of GTPase activity to LRRK2-associated Parkinson diseaseDeciphering the function of leucine-rich repeat kinase 2 and targeting its dysfunction in disease.The GTPase function of LRRK2.A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling.Targeting leucine-rich repeat kinase 2 in Parkinson's disease.LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesisCellular processes associated with LRRK2 function and dysfunctionLRRK2 Pathways Leading to Neurodegeneration.LRRK2 at the Crossroad Between Autophagy and Microtubule Trafficking: Insights into Parkinson's Disease.LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein.Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection.A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease.Mechanisms of Mutant LRRK2 Neurodegeneration.Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).
P2860
Q24296968-D9FC6785-8DB5-4FC2-B0DD-45AD511D6A5BQ24301070-6DC16752-79BF-407A-8700-2FFD5C249255Q24324345-24C2A828-4E49-4A14-8357-86DA41EAD591Q26764724-ECCAF673-CECF-45F5-AEAB-C9DEF909E62CQ27013695-B93086B9-E987-47A3-A8C5-201D6EA3FFB1Q28118311-E7A9D8B2-C1F2-41F3-A7DD-B0DDAF63DB61Q33797449-00D32721-3E31-41F5-B5E8-6EFE2CFE57FAQ36981223-E0A3B072-738F-4551-BDE7-1D4177DF44DEQ37308940-5533B87E-5F1C-4ED2-B247-FACAEADFDC19Q37513500-01917353-FE3D-45AD-B33D-35A1F74E6A50Q37595917-F3336467-0FCB-40D3-8B68-EEFF6F633FB5Q37686991-5A6BAEAF-9D1E-4EA8-A415-402DD8F182F0Q38044425-A26ECA3B-A4B4-47C0-8D68-A4C3B7FDF58CQ38044433-47160EF0-CD4C-4C05-838E-35A5C00A34A5Q38044445-5BBE12A1-B43E-41E4-BA24-B5EEB3CC0F52Q38160939-DFFEB106-76E7-46D1-BD37-BB34AC073FD8Q38218398-67C59AAB-83A4-4125-851A-AA9FA758FE7DQ38433725-DEF1B5F2-D65B-43FB-B80B-575F509E50CEQ38501861-E16055E8-6CE5-4E33-844B-1C00AE79A4A0Q38689010-712755F6-D386-45DC-80BE-3F2F5D9ED184Q39236534-042ABBAB-42AF-46E6-89CF-83E69CA56782Q39776744-2FD48593-26A6-476F-9306-2281ADCDC702Q40087652-197BF290-B8D5-47D5-9A67-9FD0A8B1CD98Q41776543-F678C57B-72A7-421C-8316-F27B9C54F61CQ48239635-DF10195D-3E65-422F-B2A4-92819CD6211AQ50860871-0F64F576-9A17-42D7-94E6-497AF1075FBF
P2860
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@ast
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@en
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@nl
type
label
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@ast
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@en
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@nl
prefLabel
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@ast
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@en
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@nl
P2860
P921
P356
P1433
P1476
Is inhibition of kinase activi ...... ssociated Parkinson's disease?
@en
P2093
Iakov N Rudenko
P2860
P2888
P356
10.1186/1741-7015-10-20
P407
P5008
P577
2012-02-23T00:00:00Z
P5875
P6179
1028902372